|
| 达格列净和沙格列汀复方制剂治疗2型糖尿病研究进展 |
| Deveolpment of Saxagliptin/Dapagliflozin, a Compound Preparation Against Type 2 Diabetes Mellitus |
| |
| DOI： |
| 中文关键词: 沙格列汀 达格列净 二甲双胍 2型糖尿病 |
| 英文关键词:Saxagliptin Dapagliflozin Metformin Type 2 diabetes mellitus |
| 基金项目: |
|
| 摘要点击次数: 1224 |
| 全文下载次数: 2290 |
| 中文摘要: |
| 摘 要沙格列汀是一种二肽基肽酶-4(DPP-4)抑制药，达格列净为钠 葡萄糖协同转运蛋白2（SGLT2）抑制药。两药复方制剂已被美国FDA批准用于成人2型糖尿病的治疗。达格列净有增加内源性葡萄糖的作用，沙格列汀降低内源性葡萄糖的作用，两药在体内没有相互作用。短期和长期的临床试验证明，两药联合应用能够很好地控制患者的血糖，低血糖的发生率很低，也不增加患者的体重。 |
| 英文摘要: |
| ABSTRACTSaxagliptin is a DPP 4 inhibitor and dapagliflozin is a SGLT2 inhibitor. The fixed dose combination tablets are approved by the USA for the improvement of glycaemic control in adults with type 2 diabetes mellitus. Dapagliflozin is able to increase endogenous glucose production, while Saxagliptin could decrease endogenous glucose production. The combination of two drugs have no interactivity in the body. Long term and short term cinical trials have showed the compound preparation could control patients’ blood glucose, few chance of hypoglycemia and no gain of patients’ weight. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
